Magnet Biomedicine, a leading biopharmaceutical company advancing molecular glue discovery with rational selection and design ...

Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's ...

The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.65 billion ...

Magnet Biomedicine, a biopharmaceutical company advancing molecular glue discovery, has entered a collaboration and license ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Ahead of whatever Jensen Huang & Co. announces, let's look at another highflying stock: Costco Wholesale (COST). Christopher Bloomstran, the president and chief investment officer St. Louis-based ...

Five researchers from Washington University in St. Louis have been named senior members of the National Academy of Inventors ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a ...

U.S. Secretary of Commerce Howard Lutnick said Lilly was doing "exactly what the President was hoping would happen." ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...